Berkeley, CAFounded 20155+ employeesPrivate
$5.1M raisedSeed· last: non equity assistance (Jun 2023)· 9 rounds
Backed by(16 investors)
BioTools Innovator · LeadSOSV · LeadNational Institute of Allergy and Infectious Diseases · LeadNSW Medical Devices Fund · LeadFounders Fund · Lead+11 more
Intracellular delivery is the most problematic step in T cell immunotherapy discovery, development and manufacturing. Indee Labs is developing a non-viral intracellular delivery system based on microfluidic vortex shedding (µVS) to rapidly deliver nucleic acids, proteins and gene editing complexes to patient and donor T cells with minimal perturbation.
